<?xml version="1.0" encoding="UTF-8"?>
<p>After antigen exposure, the expression of PD-1 on T-cells is induced rapidly, following the engagement between the T-cell receptor (TCR) and the loaded major histocompatibility complex (MHC) molecule in the draining lymph nodes [
 <xref rid="B77-pharmaceuticals-13-00096" ref-type="bibr">77</xref>]. The presence of various pro-inflammatory mediators such as IL-2, IL-6, IL-7, and IL-15 in the affected tissue contribute further to PD-1â€²s up-regulation of T-cells [
 <xref rid="B78-pharmaceuticals-13-00096" ref-type="bibr">78</xref>]. The interaction between PD-1 and PD-1L provides signals that tolerize T-cells to their antigenic targets, neutralizing their effector functions [
 <xref rid="B78-pharmaceuticals-13-00096" ref-type="bibr">78</xref>]. Furthermore, in sepsis patients, PD-1 and PD-L1 are known to be the primary mediators in T cell depletion [
 <xref rid="B79-pharmaceuticals-13-00096" ref-type="bibr">79</xref>]. Animal models have shown that blocking PD-1 or PD-L1 prevents T cell death, regulates cytokine production, and reduces both organ dysfunction and death in sepsis [
 <xref rid="B80-pharmaceuticals-13-00096" ref-type="bibr">80</xref>]. Researchers are therefore attempting to perform clinical trials to determine the effectiveness of PD-1 inhibitors in 2019 novel coronavirus infection in patients with serious lymphocytopenia-associated pneumonia.
</p>
